Wiesje M. van der Flier

Integrative analysis of cerebrospinal fluid biomarkers, metabolomics, and polygenic risk reveals novel metabolite associations with Alzheimer's disease Open

Marcelo Francia, N Ramesh, Toni Boltz, Merel Bot, Wiesje M. van der Flier , et al. · 2025

Background Cerebrospinal fluid (CSF) metabolomics offers an opportunity to investigate in vivo biological pathways impacted in the human brain by Alzheimer's disease (AD). While impairments in brain glucose metabolism and lipid homeostasis…

Characterizing individuals fulfilling clinical criteria for LATE in a tertiary memory clinic Open

Colin Groot, Ismael Luis Calandri, Ilse Bader, Diana I. Bocancea, Hannah de Bruin , et al. · 2025

Limbic-predominant age-related TDP-43 encephalopathy (LATE) is characterized by an amnestic-and limbic-predominant phenotype, which can mimic the clinical presentation of Alzheimer’s disease (AD). Differentiating between LATE and AD is imp…

Genetic testing of common and rare variants in dementia patients from a memory clinic Open

Itziar de Rojas, Marc Hulsman, Niccoló Tesi, Rosalina M.L. van Spaendonk, Jetske van der Schaar , et al. · 2025

Usability and feasibility of ADappt: a digital toolkit to support communication on diagnosis and prognosis in memory clinics Open

Heleen M.A. Hendriksen, Tanja J. de Rijke, Aniek M. van Gils, Marlijn H. de Beer, Femke H. Bouwman , et al. · 2025

Perspectives on the measurement of self‐perceived cognitive function in older adults Open

Elke Butterbrod, Laura A. Rabin, Douglas Tommet, Richard N. Jones, Mark A. Dubbelman , et al. · 2025

INTRODUCTION This survey investigated perspectives of research and clinical professionals on optimal content and features of measurement of self‐perceived cognitive functioning. METHODS Respondents were professionals working with older adu…

How can Alzheimer's disease blood‐based biomarkers reach clinical practice? Open

Robert Perneczky, Frances‐Catherine Quevenco, James A. Hendrix, Stéphane Epelbaum, Charlotte E. Teunissen , et al. · 2025

INTRODUCTION Alzheimer's disease (AD) diagnosis has been based largely on clinical symptoms, despite their limited sensitivity and specificity. Biomarker use was proposed to support a more accurate and timely diagnosis. However, neuroimagi…

Cortical thickness subtypes in cognitively unimpaired individuals: Differential network and transcriptomic vulnerability to cortical thinning Open

Luigi Lorenzini, Mario Tranfa, Leonard Pieperhoff, Federico Masserini, Mara ten Kate , et al. · 2025

INTRODUCTION The emergence, stability, and contributing factors of Alzheimer's disease (AD) gray matter subtypes remain unclear. METHODS We analyzed data from 1323 individuals without a diagnosis of dementia (CDR < 1) with T1w‐MRI and amyl…

Long‐term cost‐effectiveness of a more accurate diagnostic work‐up for dementia Open

Pieter J. van der Veere, Hana M. Broulíková, Jeroen Hoogland, Ingrid S. van Maurik, Elsmarieke van de Giessen , et al. · 2025

INTRODUCTION To address uncertainty about long‐term clinical and economic impacts of an accurate dementia diagnosis, we evaluated the cost‐effectiveness of adding amyloid positron emission tomography (PET) to memory clinic workup over 5 ye…

Opposing views or like-minded? International Working Group and Alzheimer’s Association criteria Open

Inge M.W. Verberk, Argonde C. van Harten, Wiesje M. van der Flier · 2025

The 2024 AA and IWG diagnostic criteria for Alzheimer’s disease differ in their classification of asymptomatic individuals. Verberk et al. argue, however, that their shared requirement for biomarker use in diagnosis means they are now larg…

The association of diabetes with Alzheimer's disease biomarkers and vascular burden across European aging and memory clinic cohorts Open

Veerle van Gils, Willemijn J. Jansen, Wiesje M. van der Flier, Pablo Martínez‐Lage, Jakub Hort , et al. · 2025

INTRODUCTION It remains unclear whether diabetes mellitus (DM) is associated with Alzheimer's disease (AD) pathology and associated vascular burden. METHODS We included cognitively normal (CN), mild cognitive impairment (MCI), and dementia…

Cerebrospinal fluid proteomic associations of <i>APOE</i> genotypes reveal distinct protective and risk mechanisms for Alzheimer's disease Open

Eleonora M. Vromen, Senne B. Lageman, Johan Gobom, Rik van der Kant, Valerija Dobričić , et al. · 2025

BACKGROUND The apolipoprotein E ( APOE ) gene includes the strongest protective (ε2) and risk (ε4) variants for sporadic Alzheimer's disease (AD), but underlying mechanisms remain unclear. We studied APOE genotype effects on the cerebrospi…

General practitioners’ perspectives on blood biomarkers for Alzheimer's disease Open

Thomas Claessen, F. C. Visser, Barbara C. Van Munster, Wiesje M. van der Flier, Martí Jiménez‐Mausbach , et al. · 2025

BACKGROUND Alzheimer's disease (AD) blood biomarkers could improve the diagnostic process for patients with cognitive complaints presenting to primary care. We investigated general practitioners’ (GPs’) perspectives on facilitating and hin…

Intention to use and perceived satisfaction with a digital tool for dementia prevention among the Dutch general public: a cross-sectional study Open

Tanja J. de Rijke, Leonie N.C. Visser, Kyra K.M. Kaijser, Jeroen Bruinsma, Susan J. Oudbier , et al. · 2025

Background The increasing prevalence of dementia coincides with a shrinking healthcare workforce, highlighting the importance of dementia prevention. Digital health tools are smart devices and connected equipment that improve health and ca…

Evidence‐based standardized sample handling protocol for accurate blood‐based Alzheimer's disease biomarker measurement: Results and consensus of the Global Biomarker Standardization Consortium Open

Inge M.W. Verberk, Mariam Gouda, Daniel Antwi‐Berko, Mardou van Leeuwenstijn, Bram Bongers , et al. · 2025

INTRODUCTION Blood‐based biomarkers (BBMs) have revolutionized Alzheimer's disease diagnosis and monitoring. Their pre‐analytical stability requires scrutiny. This study assessed pre‐analytical effects to inform a standardized sample handl…

Federated Fine-Tuning of SAM-Med3D for MRI-Based Dementia Classification Open

Kaouther Mouheb, Marawan Elbatel, Janne M. Papma, Geert Jan Biessels, Jurgen A.H.R. Claassen , et al. · 2025

Plasma Phosphorylated Tau 217 to Identify Preclinical Alzheimer Disease Open

Gemma Salvadó, Shorena Janelidze, Divya Bali, Anna Orduña Dolado, Joseph Therriault , et al. · 2025

Importance Advances in Alzheimer disease (AD) have shifted research focus to earlier disease stages, necessitating more scalable approaches to identify cognitively unimpaired individuals with amyloid β (Aβ) pathology. Objective To assess t…

The association between the MIND-NL diet, Dutch dietary guidelines, and global cognitive function in an older population at risk for cognitive decline Open

Sonja Beers, M.A.E. de van der Schueren, Pol Grootswagers, Ondine van de Rest, Lisa Waterink , et al. · 2025

Everyday functioning in young onset dementia: differences between diagnostic groups Open

Emma Weltings, Merel C. Postema, Maureen van Dam, Mark A. Dubbelman, Mukrabe E. Tewolde , et al. · 2025

BACKGROUND The aim of this study was to examine differences in Instrumental Activities of Daily Living (IADL) among young‐onset dementia (YOD) diagnoses. METHODS Participants were included from Amsterdam Dementia and Longitudinal Early‐Ons…

Neurodevelopment and neural environment inform Alzheimer's disease age at onset and phenotype Open

Zachary Miller, Rik Ossenkoppele, Neill R. Graff‐Radford, Isabel Elaine Allen, Wendy Shwe , et al. · 2025

INTRODUCTION Risk factors associated with sporadic non‐amnestic and early‐onset Alzheimer's disease (AD) remain underexamined. METHODS We investigated a large, clinically heterogeneous, AD cohort for frequencies of established risk factors…

New landscape of the diagnosis of Alzheimer's disease Open

Giovanni B. Frisoni, Oskar Hansson, Emma Nichols, Valentina Garibotto, Suzanne E. Schindler , et al. · 2025

Alzheimer's disease involves a drastic departure from the cognitive, functional, and behavioural trajectory of normal ageing, and is both a dreaded and highly prevalent cause of disability to individuals, and a leading source of health and…

Large-scale CSF proteome profiling identifies biomarkers for accurate diagnosis of frontotemporal dementia Open

Yanaika S. Hok‐A‐Hin, Lisa Vermunt, Carel F.W. Peeters, Emma L. van der Ende, Sterre C.M. de Boer , et al. · 2025

BACKGROUND: Diagnosis of Frontotemporal dementia (FTD) and its specific underlying neuropathologies (frontotemporal lobar degeneration; FTLD-Tau and FTLD-TDP) are challenging, and thus, fluid biomarkers are needed to improve diagnostic acc…

Connectivity as a universal predictor of tau progression in atypical Alzheimer’s disease Open

Hannah de Bruin, Colin Groot, Henryk Barthel, Gérard N. Bischof, Ganna Blazhenets , et al. · 2025

The link between regional tau load and clinical manifestation of Alzheimer’s disease (AD) highlights the importance of characterizing spatial tau distribution across disease variants. In typical (memory-predominant) AD, the spatial progres…

Soluble SORL1 in cerebrospinal fluid as a marker for functional impact of rare SORL1 variants Open

Matthijs W J de Waal, Sven J. van der Lee, Melanie Lunding, Lynn Boonkamp, Nicholas C. Barrett , et al. · 2025

Background As part of the retromer, sortilin-related receptor (SORL1) sorts cargo proteins away from the endosome to the trans-Golgi network or to the cell surface, where SORL1 is cleaved into sSORL1 and shed into the interstitial fluid an…

Modernizing diagnosis of Alzheimer's disease: A review of global trends and Asia‐specific perspectives Open

Takeshi Iwatsubo, Reisa A. Sperling, Alicia Algeciras‐Schimnich, Hidenori Arai, Anna M. Barron , et al. · 2025

The landscape of Alzheimer's disease (AD) and related dementias (ADRD) diagnosis is evolving rapidly, driven by advances in disease understanding, biomarker tools, and disease‐modifying therapies. Modern diagnostic approaches emphasize bio…

The Effects of a Multidomain Lifestyle Intervention on Brain Function and Its Relation With Immunometabolic Markers and Intestinal Health in Older Adults at Risk of Cognitive Decline: Study Design and Baseline Characteristics of the HELI Randomized Controlled Trial Open

Mark R. van Loenen, Lianne B. Remie, Mara P. H. van Trijp, Michelle G. Jansen, José P. Marques , et al. · 2025

Background Studies of multidomain lifestyle interventions show mixed results on preventing or delaying cognitive decline in aging. A better understanding of central and peripheral mechanisms underlying these interventions could help explai…

CHIT1 and DDAH1 levels relate to amyloid-related imaging abnormalities risk profile in Alzheimer’s disease patients Open

Marlies Oosthoek, Everard G.B. Vijverberg, Elena R. Blujdea, Sjors G. J. G. In ‘t Veld, Manuel Avilés , et al. · 2025

Machine learning in Alzheimer’s disease genetics Open

Matthew Bracher‐Smith, Federico Melograna, Brittany Ulm, Céline Bellenguez, Benjamin Grenier‐Boley , et al. · 2025

A large-scale multi-centre study characterising atrophy heterogeneity in Alzheimer’s disease Open

Vikram Venkatraghavan, Damiano Archetti, Pierrick Bourgeat, Chenyang Jiang, Mara ten Kate , et al. · 2025

Tau PET positivity in individuals with and without cognitive impairment varies with age, amyloid-β status, APOE genotype and sex Open

Rik Ossenkoppele, Emma M. Coomans, Liana G. Apostolova, Suzanne L. Baker, Henryk Barthel , et al. · 2025

Comment by European Alzheimer’s Disease Consortium (EADC) investigators on the negative recommendation of the CHMP on the marketing authorization of donanemab for early Alzheimer’ s disease Open

Frank Jessen, Javier Arbizu, Merçé Boada, Mircea Balasa, Karim Bennys , et al. · 2025

Wiesje M. van der Flier YOU? Author Swipe